Vimarsana
Biggest News Aggregation in the World

Liver Unit News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Liver Unit. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Liver Unit Today - Breaking & Trending Today

Israeli-German Partnership Aims to Replace Animal Experiments With Advanced Liver-on-Chip Devices - Vimarsana News

Israeli-German Partnership Aims to Replace Animal Experiments With Advanced Liver-on-Chip Devices

Bionic Liver Micro-Organs Explain Off-Target Toxicity of Acetaminophen (Tylenol)

ENDRA Life Sciences Installs First TAEUS System in the UK - Vimarsana News

ENDRA Life Sciences Installs First TAEUS System in the UK

King's College Hospital in London Leads UK Introduction of ENDRA Liver System ...

Consultant Hepatologist job with King's College Hospital NHS Foundation Trust - Vimarsana News

Consultant Hepatologist job with King's College Hospital NHS Foundation Trust

Consultant Hepatologist job in London with King's College Hospital NHS Foundation Trust. Apply Today.

Source: bmj.com
Durvalumab Treatment Regimen Reduces Risk of Disease Progression, Death in Patients With HCC - Vimarsana News

Durvalumab Treatment Regimen Reduces Risk of Disease Progression, Death in Patients With HCC

Compared to TACE alone, durvalumab plus TACE and bevacizumab reduced the risk of disease progression or death by 23%; however, further research is needed to assess OS.

IMFINZI® (durvalumab) plus transarterial chemoembolization (TACE) and bevacizumab reduced the risk of disease progression or death by 23% vs. TACE in liver cancer eligible for embolization - Vimarsana News

IMFINZI® (durvalumab) plus transarterial chemoembolization (TACE) and bevacizumab reduced the risk of disease progression or death by 23% vs. TACE in liver cancer eligible for embolization

EMERALD-1 is first global Phase III trial to show improved clinical outcome for systemic therapy in combination with TACE in this setting ...